Inhibition of ALK3-mediated signalling pathway protects against acetaminophen-induced liver injury

Autor: Patricia Marañón, Esther Rey, Stephania C. Isaza, Hanghang Wu, Patricia Rada, Carmen Choya-Foces, Antonio Martínez-Ruiz, María Ángeles Martín, Sonia Ramos, Carmelo García-Monzón, Francisco Javier Cubero, Ángela M. Valverde, Águeda González-Rodríguez
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Redox Biology, Vol 71, Iss , Pp 103088- (2024)
Druh dokumentu: article
ISSN: 2213-2317
DOI: 10.1016/j.redox.2024.103088
Popis: Acetaminophen (APAP)-induced liver injury is one of the most prevalent causes of acute liver failure (ALF). We assessed the role of the bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3 in APAP-induced hepatotoxicity. The molecular mechanisms that regulate the balance between cell death and survival and the response to oxidative stress induced by APAP was assessed in cultured human hepatocyte-derived (Huh7) cells treated with pharmacological inhibitors of ALK receptors and with modulated expression of ALK2 or ALK3 by lentiviral infection, and in a mouse model of APAP-induced hepatotoxicity. Inhibition of ALK3 signalling with the pharmacological inhibitor DMH2, or by silencing of ALK3, showed a decreased cell death both by necrosis and apoptosis after APAP treatment. Also, upon APAP challenge, ROS generation was ameliorated and, thus, ROS-mediated JNK and P38 MAPK phosphorylation was reduced in ALK3-inhibited cells compared to control cells. These results were also observed in an experimental model of APAP-induced ALF in which post-treatment with DMH2 after APAP administration significantly reduced liver tissue damage, apoptosis and oxidative stress. This study shows the protective effect of ALK3 receptor inhibition against APAP-induced hepatotoxicity. Furthermore, findings obtained from the animal model suggest that BMP signalling might be a new pharmacological target for the treatment of ALF.
Databáze: Directory of Open Access Journals